Impact of Novo Nordisk and Ozempic on Denmark's Economy

Denmark's economy is heavily reliant on the diabetes drug Ozempic, manufactured by Novo Nordisk, which has led to significant economic growth but also poses risks of imbalance and dependency on one company. Analogies are drawn to 'Dutch disease' and the 'Nokia trap' to caution against potential economic downturns if Novo Nordisk's fortunes change.